Rallybio/$RLYB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Rallybio
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
- Ticker
- $RLYB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6
- Headquarters
- New Haven, United States
- Website
- www.rallybio.com
Rallybio Metrics
BasicAdvanced
$85M
3.38
$4.65
-0.77
-
Price and volume
Market cap
$85M
Beta
-0.77
52-week high
$17.57
52-week low
$3.67
Average daily volume
24K
Financial strength
Current ratio
28.867
Quick ratio
27.625
Profitability
EBITDA (TTM)
-21.913
Gross margin (TTM)
-1,344.24%
Net profit margin (TTM)
6,177.42%
Operating margin (TTM)
-5,050.92%
Effective tax rate (TTM)
4.98%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-16.79%
Return on equity (TTM)
34.52%
Valuation
Price to earnings (TTM)
3.385
Price to revenue (TTM)
206.728
Price to book
0.91
Price to tangible book (TTM)
0.91
Price to free cash flow (TTM)
2.895
Free cash flow yield (TTM)
34.54%
Free cash flow per share (TTM)
5.44
Growth
Revenue change (TTM)
-35.61%
Earnings per share change (TTM)
-283.84%
3-year earnings per share growth (CAGR)
-31.37%
Rallybio Financial Performance
Revenues and expenses
Rallybio Earnings Performance
Company profitability
Upcoming events
Rallybio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.